CN1655784A - 有效的选择性阿片受体调制剂化合物的用途 - Google Patents
有效的选择性阿片受体调制剂化合物的用途 Download PDFInfo
- Publication number
- CN1655784A CN1655784A CNA038111373A CN03811137A CN1655784A CN 1655784 A CN1655784 A CN 1655784A CN A038111373 A CNA038111373 A CN A038111373A CN 03811137 A CN03811137 A CN 03811137A CN 1655784 A CN1655784 A CN 1655784A
- Authority
- CN
- China
- Prior art keywords
- chemical compound
- effective
- purposes
- colon
- asimadoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
99mTc膳食 | 成像 | ||||||
间隔(h) | 0 | 1 | 2 | 3 | 4 | 6 | |
时间 | 8:00 | 8:00 | 9:00 | 10:00 | 11:00 | 12:00 | 14:00 |
111InCl3膳食 | 成像 | ||||||
间隔(h) | 4 | 6 | 8 | 24 | 32 | 48 | |
时间 | 7:00 | 11:00 | 13:00 | 15:00 | 7:00 | 15:00 | 7:00 |
反应 | CV+(%) | 可检测的效果大小(%)* | |
80%强度 | 90%强度 | ||
GE@2hrs | 43% | 38% | 44% |
GE@24hrs | 38% | 34% | 39% |
CF@6hrs | 51% | 45% | 52% |
饱满体积 | 25% | 22% | 26% |
禁食结肠紧张性 | 41% | 36% | 42% |
结肠膳食反应 | 43% | 38% | 44% |
GC@4hrs | 65% | 58% | 67% |
反应 | CV(%)2 | 可检测的效果大小(%)1 | |||
80%强度 | 90%强度 | ||||
N=20 | N=403 | N=20 | N=403 | ||
胀气8mmHg | 103% | 91% | 79% | 106% | 91% |
胀气16mmHg | 80% | 71% | 61% | 82% | 71% |
胀气24mmHg | 80% | 71% | 61% | 82% | 71% |
胀气32mmHg | 75% | 66% | 58% | 77% | 67% |
疼痛8mmHg | 92% | 82% | 71% | 94% | 82% |
疼痛16mmHg | 90% | 80% | 69% | 92% | 80% |
疼痛24mmHg | 78% | 69% | 60% | 80% | 69% |
总体胀气得分4 | 73% | 65% | 56% | 75% | 65% |
总体疼痛得分4 | 71% | 63% | 54% | 73% | 63% |
总体综合得分4 | 61% | 54% | 47% | 63% | 54% |
Claims (21)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02011047.4 | 2002-05-17 | ||
EP02011047 | 2002-05-17 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2008101295692A Division CN101310723A (zh) | 2002-05-17 | 2003-04-28 | 有效的选择性阿片受体调制剂化合物的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1655784A true CN1655784A (zh) | 2005-08-17 |
CN100411618C CN100411618C (zh) | 2008-08-20 |
Family
ID=29433078
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB038111373A Expired - Fee Related CN100411618C (zh) | 2002-05-17 | 2003-04-28 | 有效的选择性阿片受体调制剂化合物的用途 |
CNA2008101295692A Pending CN101310723A (zh) | 2002-05-17 | 2003-04-28 | 有效的选择性阿片受体调制剂化合物的用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2008101295692A Pending CN101310723A (zh) | 2002-05-17 | 2003-04-28 | 有效的选择性阿片受体调制剂化合物的用途 |
Country Status (21)
Country | Link |
---|---|
US (1) | US20050176746A1 (zh) |
EP (2) | EP1505974B1 (zh) |
JP (1) | JP2005531557A (zh) |
KR (1) | KR101108014B1 (zh) |
CN (2) | CN100411618C (zh) |
AR (1) | AR040028A1 (zh) |
AT (1) | ATE429226T1 (zh) |
AU (1) | AU2003242527B2 (zh) |
BR (1) | BR0309969A (zh) |
CA (1) | CA2486000A1 (zh) |
DE (1) | DE60327315D1 (zh) |
DK (1) | DK1505974T3 (zh) |
ES (1) | ES2325782T3 (zh) |
HK (1) | HK1079451A1 (zh) |
MX (1) | MXPA04011333A (zh) |
PE (1) | PE20040455A1 (zh) |
PL (1) | PL371596A1 (zh) |
RU (1) | RU2336871C2 (zh) |
TW (1) | TWI314053B (zh) |
WO (1) | WO2003097051A2 (zh) |
ZA (1) | ZA200410160B (zh) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10259245A1 (de) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Derivate des Asimadolins mit kovalent gebundenen Säuren |
DK1594517T3 (da) | 2003-01-28 | 2007-10-29 | Microbia Inc | Sammensætninger til behandlingen af gastrointestinale lidelser |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP1870096A3 (en) * | 2003-04-29 | 2011-04-20 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
ES2760464T3 (es) | 2003-04-29 | 2020-05-14 | Nalpropion Pharmaceuticals Inc | Composiciones para afectar a la pérdida de peso |
CA2544245A1 (en) * | 2003-10-30 | 2005-05-26 | Tioga Pharmaceuticals, Inc. | Use of selective opiate receptor modulators in the treatment of neuropathy |
BRPI0618918B8 (pt) | 2005-11-22 | 2021-05-25 | Nalpropion Pharmaceuticals Llc | uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
CN101573103A (zh) | 2006-11-09 | 2009-11-04 | 奥雷西根治疗公司 | 用于施用重量减轻药物的单位剂量包装和方法 |
RU2441655C2 (ru) * | 2007-03-30 | 2012-02-10 | Тиога Фармасьютикалз Инк. | Агонисты каппа-опиоидов для лечения синдрома раздраженного кишечника с преобладанием диареи и перемежающегося синдрома раздраженного кишечника |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CN101772513B (zh) | 2007-06-04 | 2013-11-13 | 协同医药品公司 | 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂 |
WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
EP2328910B1 (en) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2010065751A2 (en) | 2008-12-03 | 2010-06-10 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
KR101683318B1 (ko) | 2008-12-31 | 2016-12-07 | 알데릭스, 인코포레이티드 | 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 nhe-매개된 역수송을 억제하는 화합물 및 방법 |
WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
KR20120124423A (ko) | 2010-01-11 | 2012-11-13 | 오렉시젠 세러퓨틱스 인크. | 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법 |
US9303027B2 (en) | 2010-07-19 | 2016-04-05 | Dr. Reddy's Laboratories Ltd. | Kappa opioid receptor agonists |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
WO2012118972A2 (en) | 2011-03-01 | 2012-09-07 | Synegy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
PL2858640T3 (pl) | 2012-06-06 | 2020-10-05 | Nalpropion Pharmaceuticals Llc | Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym |
KR102138390B1 (ko) | 2012-08-21 | 2020-07-27 | 알데릭스, 인코포레이티드 | 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료에서 nhe-매개된 역수송 저해를 위한 화합물 및 방법 |
US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
US9675587B2 (en) | 2013-03-14 | 2017-06-13 | Allergan Holdings Unlimited Company | Opioid receptor modulator dosage formulations |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
CA2909169A1 (en) | 2013-04-12 | 2014-10-16 | Ardelyx, Inc. | Nhe3-binding compounds and methods for inhibiting phosphate transport |
CA2913737A1 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
EA023231B1 (ru) * | 2013-07-18 | 2016-05-31 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН) | Применение агониста каппа опиоидных рецепторов периферического действия ici 204,448 для приготовления средств для лечения синдрома отмены никотина |
US20160250277A1 (en) * | 2013-10-28 | 2016-09-01 | Cara Therapeutics, Inc. | Peripheral kappa opioid receptor agonists for preventing, inhibiting or treating nausea and vomiting |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
EP3565811A1 (en) | 2017-01-09 | 2019-11-13 | Ardelyx, Inc. | Inhibitors of nhe-mediated antiport |
KR20240090875A (ko) | 2017-01-09 | 2024-06-21 | 알데릭스, 인코포레이티드 | 위장관 장애를 치료하는 데 유용한 화합물 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4889860A (en) * | 1985-09-23 | 1989-12-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
DE3935371A1 (de) | 1988-12-23 | 1990-07-05 | Merck Patent Gmbh | Stickstoffhaltige ringverbindungen |
DE4034785A1 (de) | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | 1-(2-arylethyl)-pyrrolidine |
US5389686A (en) * | 1989-02-20 | 1995-02-14 | Jouveinal Sa | Analgesic properties of fedotozine |
DE4215213A1 (de) | 1992-05-09 | 1993-11-11 | Merck Patent Gmbh | Arylacetamide |
DE4215231C1 (en) | 1992-05-09 | 1993-05-13 | Dornier Luftfahrt Gmbh, 8031 Wessling, De | Arrangement for mfg. fibre reinforced thermoplastic components - including unit for accommodating component, pressurising unit for assembled component and heating unit |
DE19523502A1 (de) | 1995-06-28 | 1997-01-02 | Merck Patent Gmbh | Kappa-Opiatagonisten für entzündliche Darmerkrankungen |
DE19531464A1 (de) * | 1995-08-26 | 1997-02-27 | Merck Patent Gmbh | N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid |
RU2234337C2 (ru) * | 1997-09-26 | 2004-08-20 | Ноувен Фамэсьютикэлз, Инк. | Биоадгезивная композиция (варианты), способ ее получения (варианты), устройство для доставки через слизистую оболочку активного агента, способ пролонгированного местного введения одного или более активных агентов субъекту (варианты) и способ сокращения времени, требуемого для приклеивания композиции к слизистой ткани |
US20010051181A1 (en) * | 1997-12-22 | 2001-12-13 | Van Osdol William W. | Novel formulations for the transdermal administration of asimadoline |
JPH11343244A (ja) * | 1998-03-30 | 1999-12-14 | Taisho Pharmaceut Co Ltd | 経口用組成物 |
JP2000080047A (ja) * | 1998-06-30 | 2000-03-21 | Takeda Chem Ind Ltd | 医 薬 |
DE69933771T2 (de) * | 1998-07-14 | 2007-09-13 | Janssen Pharmaceutica N.V. | Neurotrophischer wachstumsfaktor |
DK1033364T3 (da) * | 1999-03-01 | 2005-06-06 | Pfizer Prod Inc | Cyanholdige oxamidsyrer og -derivater som thyroideareceptorligander |
JP2005508830A (ja) * | 2000-06-19 | 2005-04-07 | エーザイ株式会社 | ピリジン誘導体を用いる方法 |
GB0015562D0 (en) * | 2000-06-23 | 2000-08-16 | Pfizer Ltd | Heterocycles |
US6262062B1 (en) * | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
US6569449B1 (en) * | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
WO2003048113A1 (en) * | 2001-11-30 | 2003-06-12 | Sepracor Inc. | Tramadol analogs and uses thereof |
-
2003
- 2003-04-28 AT AT03752716T patent/ATE429226T1/de not_active IP Right Cessation
- 2003-04-28 CA CA002486000A patent/CA2486000A1/en not_active Abandoned
- 2003-04-28 WO PCT/EP2003/004428 patent/WO2003097051A2/en active Application Filing
- 2003-04-28 CN CNB038111373A patent/CN100411618C/zh not_active Expired - Fee Related
- 2003-04-28 PL PL03371596A patent/PL371596A1/xx not_active Application Discontinuation
- 2003-04-28 EP EP03752716A patent/EP1505974B1/en not_active Expired - Lifetime
- 2003-04-28 RU RU2004137091/15A patent/RU2336871C2/ru not_active IP Right Cessation
- 2003-04-28 BR BR0309969-5A patent/BR0309969A/pt not_active Application Discontinuation
- 2003-04-28 EP EP09158047A patent/EP2074997A1/en not_active Withdrawn
- 2003-04-28 MX MXPA04011333A patent/MXPA04011333A/es active IP Right Grant
- 2003-04-28 DK DK03752716T patent/DK1505974T3/da active
- 2003-04-28 ES ES03752716T patent/ES2325782T3/es not_active Expired - Lifetime
- 2003-04-28 AU AU2003242527A patent/AU2003242527B2/en not_active Ceased
- 2003-04-28 US US10/514,887 patent/US20050176746A1/en not_active Abandoned
- 2003-04-28 JP JP2004505050A patent/JP2005531557A/ja active Pending
- 2003-04-28 CN CNA2008101295692A patent/CN101310723A/zh active Pending
- 2003-04-28 DE DE60327315T patent/DE60327315D1/de not_active Expired - Lifetime
- 2003-04-28 KR KR1020047018468A patent/KR101108014B1/ko not_active IP Right Cessation
- 2003-05-12 TW TW092112843A patent/TWI314053B/zh not_active IP Right Cessation
- 2003-05-13 PE PE2003000457A patent/PE20040455A1/es not_active Application Discontinuation
- 2003-05-16 AR ARP030101709A patent/AR040028A1/es unknown
-
2004
- 2004-12-15 ZA ZA2004/10160A patent/ZA200410160B/en unknown
-
2005
- 2005-12-19 HK HK05111679.0A patent/HK1079451A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2005531557A (ja) | 2005-10-20 |
EP1505974A2 (en) | 2005-02-16 |
HK1079451A1 (en) | 2006-04-07 |
DE60327315D1 (de) | 2009-06-04 |
WO2003097051A2 (en) | 2003-11-27 |
AU2003242527A1 (en) | 2003-12-02 |
ATE429226T1 (de) | 2009-05-15 |
TWI314053B (en) | 2009-09-01 |
RU2336871C2 (ru) | 2008-10-27 |
PL371596A1 (en) | 2005-06-27 |
AR040028A1 (es) | 2005-03-09 |
RU2004137091A (ru) | 2005-09-10 |
EP1505974B1 (en) | 2009-04-22 |
DK1505974T3 (da) | 2009-08-17 |
ZA200410160B (en) | 2005-12-28 |
KR20050010807A (ko) | 2005-01-28 |
KR101108014B1 (ko) | 2012-01-25 |
EP2074997A1 (en) | 2009-07-01 |
WO2003097051A3 (en) | 2004-12-09 |
CN101310723A (zh) | 2008-11-26 |
AU2003242527B2 (en) | 2008-10-23 |
TW200307541A (en) | 2003-12-16 |
MXPA04011333A (es) | 2005-02-14 |
CA2486000A1 (en) | 2003-11-27 |
PE20040455A1 (es) | 2004-08-07 |
BR0309969A (pt) | 2005-04-26 |
ES2325782T3 (es) | 2009-09-17 |
CN100411618C (zh) | 2008-08-20 |
US20050176746A1 (en) | 2005-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1655784A (zh) | 有效的选择性阿片受体调制剂化合物的用途 | |
CN1162156C (zh) | 奥氮平与氟西汀在制备治疗精神病药物中的用途 | |
CN1305850C (zh) | 作为组蛋白脱乙酰酶新颖抑制剂的磺酰基氨基衍生物 | |
CN1639125A (zh) | 新的组织蛋白去乙酰酶抑制剂 | |
CN1642931A (zh) | 用作新颖的组蛋白去乙酰酶抑制剂的磺酰基衍生物 | |
CN1893952A (zh) | 用于治疗移植排斥的吡咯并[2,3-d]嘧啶化合物 | |
CN1154496C (zh) | 奥氮平和氟西汀在制备治疗对抗治疗的严重抑郁症的药物中的应用 | |
CN1639110A (zh) | 卤代乙酰胺和叠氮化物取代的化合物及其使用方法 | |
CN1523982A (zh) | 减少体脂和调节脂肪酸代谢的方法、化合物和组合物 | |
CN1700923A (zh) | 多取代的选择性雄激素受体调节剂及其使用方法 | |
CN1694864A (zh) | N-桥连选择性雄激素受体调节剂及其使用方法 | |
CN1192680A (zh) | 抑制接合蛋白/酪氨酸激酶相互作用的方法与组合物 | |
CN1805938A (zh) | 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物 | |
CN1088205A (zh) | 苯并噻吩及其相关物的改进 | |
CN1784221A (zh) | 影响体重减轻的组合物 | |
CN1366881A (zh) | 用雌激素激动剂/拮抗剂治疗某些癌症的方法 | |
CN1604968A (zh) | 基于tcf1基因多态性治疗糖尿病和相关病症的方法 | |
CN1143848C (zh) | 用作毒蕈碱性受体拮抗剂的2-芳基乙基-(哌啶-4-基甲基)胺衍生物 | |
CN1486180A (zh) | 用nmda受体拮抗物治疗神经精神病紊乱的方法 | |
CN1302207A (zh) | 双相性精神障碍的联合治疗 | |
CN1771037A (zh) | 包含噻吩并[2,3-c]吡啶衍生物的药用组合物及其用途 | |
CN1993356A (zh) | 作为组蛋白脱乙酰基酶新颖抑制剂的取代丙烯基哌嗪衍生物 | |
CN1585770A (zh) | 回折模拟物及其相关的方法 | |
CN1520314A (zh) | 含有食糜酶抑制剂和ace抑制剂作为有效成分的药物 | |
CN1165293C (zh) | 5ht4激动剂或拮抗剂的新型口服制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1079451 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: DIOGA PHARMACEUTICAL COMPANY Free format text: FORMER OWNER: MERCK PATENT GMBH Effective date: 20070727 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20070727 Address after: American California Applicant after: Merck Patent GmbH Address before: Darmstadt Applicant before: Merck Patent GmbH |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1079451 Country of ref document: HK |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080820 Termination date: 20140428 |